Invivoscribe Submits Pre-Market Approval Application in Japan and Panel Track Supplement in the US to Screen Acute Myeloid Leukemia (AML) Patients for FLT3 Mutations
Invivoscribe Technologies, Inc. announced today that they have submitted to Japan's Pharmaceutical and Medical Devices Agency (PMDA) and the US Food and Drug Administ...